Sunday, 3 March 2024

Business News

Eli Lilly & Co (LLY) Receives a Buy from Jefferies – TipRanks Financial Blog

Unity Biotechnology reports Q3 EPS ($1.36), consensus ($1.65)

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLYResearch Report) today and set a price target of $853.00. The company’s shares closed yesterday at $737.26.

According to TipRanks, Tewari is a 5-star analyst with an average return of 20.2% and a 58.49% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Regeneron, Argenx Se, and Merck & Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $770.50 average price target, a 4.51% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $825.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $745.70 and a one-year low of $307.17. Currently, Eli Lilly & Co has an average volume of 3.12M.

Based on the recent corporate insider activity of 175 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eli Lilly & Co (LLY) Company Description:

Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.

Read More on LLY:

Click Here to Read the Full Original Article at TipRanks Financial Blog…